Self-transfers and factors associated with successful tracing among persons lost to follow-up from HIV care, Sheema District, Southwestern Uganda: retrospective medical records review, 2017-2021.


Journal

AIDS research and therapy
ISSN: 1742-6405
Titre abrégé: AIDS Res Ther
Pays: England
ID NLM: 101237921

Informations de publication

Date de publication:
20 09 2022
Historique:
received: 25 05 2022
accepted: 12 09 2022
entrez: 20 9 2022
pubmed: 21 9 2022
medline: 24 9 2022
Statut: epublish

Résumé

Due to improved coverage and scale-up of antiretroviral therapy (ART), patients are increasingly transferring between ART-providing sites. Self-transfers may constitute a high proportion of patients considered lost to follow-up (LTFU), and if overlooked when reporting patients who have dropped out of HIV care, may result in an incorrect estimation of retention. We determined the prevalence of self-transfers, and successful tracing, and identified associated factors among people living with HIV (PLHIV) LTFU from care at public health facilities in Sheema District, Southwestern Uganda. We conducted a cross-sectional retrospective medical records review during February and March 2022. We included records of all PLHIV who were LTFU from 2017 to 2021, and who were registered at government-owned ART clinics in Sheema District. LTFU was considered for those who were not taking ART refills for a period of ≥ 3 months. We abstracted demographic and clinical data from medical records at the selected clinics. Participants were traced via phone calls or in-person to ascertain the outcomes of LTFU. We performed multivariate modified Poisson regression to identify factors associated with self-transfer, and successful tracing. Overall, 740 patients were identified as LTFU from three ART-providing clinics; of these, 560 (76%) were self-transfers. The mean age was 30 (SD ± 10) years, and most (69%, n = 514) were female; the majority (87%, 641/740) were successfully traced. Age (adjusted prevalence ratio [aPR] = 1.13, 95% CI 1.01-1.25, P = 0.026 for those aged 18-30 years compared to > 30 years), female sex (aPR = 1.18, 95% CI 1.11-1.25, P < 0.001), and having WHO clinical stage 1-2 (aPR = 2.34, 95% CI 1.89-3.91, P < 0.001) were significantly associated with self-transfer. Presence of a phone contact in the patient's file (aPR = 1.10, 95% CI 1.01-1.90, P = 0.026) was associated with successful tracing of the patients considered LTFU. Self-transfers accounted for the majority of patients recorded as LTFU, highlighting the need to account for self-transfers among patients considered LTFU, to accurately estimate retention in care. ART-providing facilities should regularly update contact information for PLHIV to enable successful tracing, in the event that the patients are LTFU. This calls for a health-tracking system that easily identifies self-transfers across ART-providing clinics using unique patient identifiers.

Sections du résumé

BACKGROUND
Due to improved coverage and scale-up of antiretroviral therapy (ART), patients are increasingly transferring between ART-providing sites. Self-transfers may constitute a high proportion of patients considered lost to follow-up (LTFU), and if overlooked when reporting patients who have dropped out of HIV care, may result in an incorrect estimation of retention. We determined the prevalence of self-transfers, and successful tracing, and identified associated factors among people living with HIV (PLHIV) LTFU from care at public health facilities in Sheema District, Southwestern Uganda.
METHODS
We conducted a cross-sectional retrospective medical records review during February and March 2022. We included records of all PLHIV who were LTFU from 2017 to 2021, and who were registered at government-owned ART clinics in Sheema District. LTFU was considered for those who were not taking ART refills for a period of ≥ 3 months. We abstracted demographic and clinical data from medical records at the selected clinics. Participants were traced via phone calls or in-person to ascertain the outcomes of LTFU. We performed multivariate modified Poisson regression to identify factors associated with self-transfer, and successful tracing.
RESULTS
Overall, 740 patients were identified as LTFU from three ART-providing clinics; of these, 560 (76%) were self-transfers. The mean age was 30 (SD ± 10) years, and most (69%, n = 514) were female; the majority (87%, 641/740) were successfully traced. Age (adjusted prevalence ratio [aPR] = 1.13, 95% CI 1.01-1.25, P = 0.026 for those aged 18-30 years compared to > 30 years), female sex (aPR = 1.18, 95% CI 1.11-1.25, P < 0.001), and having WHO clinical stage 1-2 (aPR = 2.34, 95% CI 1.89-3.91, P < 0.001) were significantly associated with self-transfer. Presence of a phone contact in the patient's file (aPR = 1.10, 95% CI 1.01-1.90, P = 0.026) was associated with successful tracing of the patients considered LTFU.
CONCLUSION
Self-transfers accounted for the majority of patients recorded as LTFU, highlighting the need to account for self-transfers among patients considered LTFU, to accurately estimate retention in care. ART-providing facilities should regularly update contact information for PLHIV to enable successful tracing, in the event that the patients are LTFU. This calls for a health-tracking system that easily identifies self-transfers across ART-providing clinics using unique patient identifiers.

Identifiants

pubmed: 36127692
doi: 10.1186/s12981-022-00471-2
pii: 10.1186/s12981-022-00471-2
pmc: PMC9487036
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

44

Subventions

Organisme : FIC NIH HHS
ID : R25 TW011210
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

BMJ Open. 2018 Apr 20;8(4):e017487
pubmed: 29678963
J Int AIDS Soc. 2014 Aug 01;17:19032
pubmed: 25095831
S Afr Med J. 2007 Sep;97(9):853-7
pubmed: 17985056
PLoS One. 2009 Jun 04;4(6):e5790
pubmed: 19495419
J Int AIDS Soc. 2016 Dec 01;19(1):21484
pubmed: 27914186
J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):e52-9
pubmed: 22217680
J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):e15-e18
pubmed: 28394821
PLoS Med. 2017 Apr 11;14(4):e1002268
pubmed: 28399160
BMC Med Res Methodol. 2003 Oct 20;3:21
pubmed: 14567763
Trop Med Int Health. 2015 Mar;20(3):365-79
pubmed: 25418366
PLoS One. 2020 Apr 7;15(4):e0217606
pubmed: 32255796
Trop Med Int Health. 2010 Jun;15 Suppl 1:1-15
pubmed: 20586956
BMC Infect Dis. 2011 Jan 27;11:31
pubmed: 21272350
J Int Assoc Provid AIDS Care. 2015 Nov-Dec;14 Suppl 1:S3-S34
pubmed: 26527218
Trop Med Health. 2019 Nov 06;47:52
pubmed: 31719791
Trop Med Int Health. 2010 Jun;15 Suppl 1:63-9
pubmed: 20586962
AIDS. 2012 Oct 23;26(16):2059-67
pubmed: 22781227
Implement Sci. 2017 Apr 4;12(1):45
pubmed: 28376834
PLoS One. 2013;8(3):e57907
pubmed: 23472118
J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):101-7
pubmed: 17971708

Auteurs

Arnold Ssemwogerere (A)

Department of Pharmacy, Mbarara University of Science and Technology, Mbarara, Uganda.

Javilla Kakooza Kamya (JK)

Department of Internal Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.

Lillian Nuwasasira (L)

Department of Pharmaceutical Sciences, Mbarara University of Science and Technology, Mbarara, Uganda.

Claire Ahura (C)

Department of Nursing, Mbarara University of Science and Technology, Mbarara, Uganda.

Derrick Isaac Isooba (DI)

Department of Medical Laboratory Sciences, Mbarara University of Science and Technology, Mbarara, Uganda.

Edith K Wakida (EK)

Department of Medical Education, California University of Science and Medicine, San Bernardino, USA.
Office of Research Administration, Mbarara University of Science and Technology, Mbarara, Uganda.

Celestino Obua (C)

Office of Research Administration, Mbarara University of Science and Technology, Mbarara, Uganda.
Office of the Vice Chancellor, Mbarara University of Science and Technology, Mbarara, Uganda.

Richard Migisha (R)

Department of Physiology, Mbarara University of Science and Technology, P.O BOX 1410, Mbarara, Uganda. rmigisha@must.ac.ug.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH